ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2015.2627 ETM-0-0-2627 Articles Clinical efficacy of ‘Spleen-kidney-care’ Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy LIUHONG 1 ZHENGJIN 1 LIRONG-HENG 2 Department of Nephrology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, P.R. China Cooperation Department of Chinese and Western Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China Correspondence to: Dr Jin Zheng, Department of Nephrology, Chongqing Hospital of Traditional Chinese Medicine, 6 Panxi Bypass Road, Chongqing 400021, P.R. China, E-mail: zhengjin899@163.com 09 2015 07 07 2015 10 3 1096 1102 28022014 19082014 Copyright © 2015, Spandidos Publications 2015

The aim of the present study was to investigate the effect of the traditional Chinese medicine (TCM), ‘Spleen-kidney-care’ Yiqi Huayu and Jiangzhuo decoction (SKC-YJ), as an adjuvant therapy in diabetic nephropathy (DN) treatment. In total, 72 patients with DN were randomly divided into control (n=54) and experimental (n=18) groups, with the latter administered SKC-YJ treatment. Indicators for determining the condition of the patients included the levels of proteinuria, blood glucose, glycosylated hemoglobin, blood lipids, blood viscosity and C-reactive protein, which were used to analyze the treatment protocols for DN. Following SKC-YJ treatment, the urinary albumin excretion rate, fasting blood glucose, 2 h-postprandial blood glucose, glycosylated hemoglobin, triglyceride, total cholesterol, blood viscosity, fibrinogen and C-reactive protein levels were detected in the two groups, and were all demonstrated to decrease significantly following treatment with SKC-YJ. Furthermore, the results revealed that SKC-YJ treatment exhibited no significant side-effects on the blood, liver and renal functions or gastrointestinal reactions. By contrast, SKC-YJ improved the symptoms of nausea, vomiting and diarrhea in the patients with DN, while showing no allergic reaction during the observation period. Therefore, SKC-YJ treatment was shown to significantly improve the clinical efficacy of DN treatment, illustrating novel roles for TCM in DN treatment.

 diabetic nephropathy Yiqi Huayu Jiangzhuo decoction blood viscosity traditional Chinese medicine treatment for diabetic traditional Chinese medicine syndromes Introduction

An increasing number of studies have revealed that the incidence of diabetes is based on the relative or absolute deficiency of insulin secretion from islet β-cells, which is caused by high levels of blood glucose (1–3). Diabetes is characterized by chronic, systemic metabolic disorders, while diabetic nephropathy (DN) is a systemic complication of diabetes. DN is a progressive kidney disease caused by angiopathy of the capillaries in the kidney glomeruli (4) and is characterized by nephrotic syndrome and diffuse glomerulosclerosis. DN is one of the most serious, chronic complications of diabetes, seriously affecting the life of patients, and in certain cases, resulting in mortality (5).

According to traditional Chinese medicine (TCM) syndrome differentiation typing, DN is classified as a variety of types, including ‘Thirsty’, ‘Consumption’ and ‘Edema’ (6). Specifically, DN is associated with congenital deficiency, diet, emotional disorders, excessive labor and fever. Currently, TCM considers the pathogenesis of DN to be involved in spleen and kidney deficiency. Qi is the driving force of life activities and Yin is the material basis of life activities (7). Damage of Qi is more common in early DN (8), and as the disease progresses, DN gradually causes the damage of Yin (8–10).

Disease of the islet β-cells is closely associated with the spleen (11). Modern medicine and TCM considers the kidney to be associated with the nervous, endocrine, reproductive, exercise, breathing, digestion, water metabolism, blood and immune systems, as well as other abnormal physiological functions (12–16). A previous study indicated that replenishing the kidney to regulate the peripheral tissue insulin response and glucose tolerance in the treatment of DN may reduce the blood sugar level caused by glomerular filtration, and reduce proteinuria (12). A number of studies have found that the levels of 17-hydroxycorticosteroids are generally lower in patients with kidney deficiency compared with healthy individuals, with half of the patients exhibiting a delayed reaction for the adrenocorticotropic hormone on the second infusion test (ACTH test), indicating that patients with kidney deficiency have an altered pituitary-adrenal system (16–19).

Currently, clinical use of TCM in spleen-kidney-care has achieved a certain therapeutic effect for diabetes (20). Spleen-kidney-care Yiqi Huayu and Jiangzhuo decoction (SKC-YJ) is a TCM compound that has been previously applied in DN treatment (21). In the present study, the urinary albumin excretion rate (UAER), fasting blood glucose (FBG), 2 h-postprandial blood glucose (PBG), glycosylated hemoglobin (HBAlc), triglyceride (TG), total cholesterol (TC), blood viscosity, fibrinogen (Fib) and C-reactive protein (CRP) levels were investigated following treatment with SKC-YJ. The side-effects of SKC-YJ treatment on the blood, liver, gastrointestinal and renal functions were also analyzed. Thus, the aim of the present study was to investigate the effect of SKC-YJ on DN treatment.

 Patients and methods <sec> <title>Patients and demographic data

A total of 72 patients with DN were recruited into the study (22). During the treatment, four cases withdrew from the treatment group, while two cases withdrew from the control group. The treatment group included 28 males and 22 females, with an average age of 61±9 years and an average diabetes duration of 8.4±5.2 years. The control group included nine males and seven females, with an average age of 60±11 years and an average diabetes duration of 7.9±5.2 years. The study was approved and registered in the Chongqing Hospital of TCM (Chongqing, China) in 2011. The Ethics Committee approved the screening, treatment and data collection of the patients, and all the subjects provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki.

 Treatment procedure

The two groups of patients were asked to control their diet by limiting their protein intake (0.8 mg/kg body weight per meal per day). Patients in the two groups were administered insulin aspart (dose adjusted according to the patient conditions; Novo Nordisk, Bagsvaerd, Denmark) or oral hypoglycemic agents to control their blood glucose levels (FBG, <7.0 mmol/l; PBG, <10.0 mmol/l). Patients with high blood pressure were administered losartan potassium tablets to reduce their blood pressure (≤130/80 mmHg), while those with hyperlipemia were administered simvastatin to control the level of cholesterol.

Patients in the SKC-YJ treatment group were administered the SKC-YJ compound containing the following prescription: Radix Rehmanniae (20 g), Rhizoma Dioscoreae (20 g), Fructus Corni (15 g), Fructus Psoraleae (20 g), Fructus Rosae Laevigakea (15 g), Codonopsis pilosula (30 g), Poria (30 g), Rhizoma Atractylodis Macrocephalae (15 g), Elecampane (15 g), Astragalus (30 g), Angelica sinensis (12 g), Salvia miltiorrhiza (30 g), Rhizoma Curcuma (12 g), leech powder (3 g), coix seed (30 g), Alisma (15 g) and cooked rhubarb (6 g). SKC-YJ was administered three times/day for one month. In the control group, piperazine tablets were administered three times/day for one month.

 Measurement parameter

Following treatment for one month, the 24 h-urine protein concentration (g/24 h) and 24 h-urine volume were recorded (C16200; Abbott Laboratories, North Chicago, IL, USA). Samples of fasting blood (3 ml) were collected to monitor the levels of FBG, HBAlc, TC, TG and CRP. HBAlc was tested using an HA-8160 analyzer (Arkray Factory, Inc., Shiga, Japan), while the levels of FBG, TC, TG and CRP were detected using a DCA Vantage Analyzer, (Siemens Healthcare Global, Erlangen, Germany). An automatic blood viscosity analyzer (LBY-N6Compact; Precil Medical Company, Beijing, China) was used to measure the whole blood viscosity at high cut (BVH) and at low cut (BVL), the plasma viscosity (PV), red blood cell aggregation index (RBCAI), red blood cell electrophoresis time (RBCET), whole blood reduced viscosity (BRV) and the level of Fib. Following breakfast, 0.2-ml samples of 2 h-postprandial blood were collected for a glucose test.

 Outcome evaluation

The two groups were compared prior to and following treatment. The treatment effect was considered to be significant if the levels of 24 h-urinary protein were <1 g or >50% lower compared with prior treatment, FBG was <6.1 mmol/l, PBG was <11.1 mmol/l, HBAlc was <6.0%, TC was <5.2 mmol/l and TG ester was <1.7 mmol/l. The treatment was considered to be effective if the level of 24 h-urinary protein was <2 g or >30% lower compared with prior treatment, FBG was <7.0 mmol/l, PBG was <12.1 mmol/l, HBAlc was <6.5%, TC was <6.0 mmol/l and TG ester was <2.0 mmol/l. The treatment was considered to be invalid if the level of 24 h-urinary protein was ≥2 g or <30% lower compared with prior treatment, FBG was >7.0 mmol/l, PBG was >12.1 mmol/l, HBAlc was >6.5%, TC was >6.0 mmol/l and TG ester was >2.0 mmol/l. Table I lists the standard indices of blood rheology, including BVH, BVL, PV, RBCAI, RBCET, BRV and Fib, which were assigned on the basis of a previous study (23).

 Statistical analysis

SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. All the data are expressed as the mean ± standard deviation. The χ2 test was used for count data comparisons, while the Student's t-test was used for inner group comparisons. In addition, measurement data were compared between groups using analysis of variance. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient demographics

Following the voluntary principles, 72 patients with DN were divided into SKC-YJ treatment (n=54) and control (n=18) groups, according to the minimum distribution requirements for allocation. Following treatment, four cases in the experimental group and two cases in the control group withdrew from the study. The tested or measured data in the two groups are listed in Table II. Following analysis, the results revealed that there were no statistically significant differences (P>0.05) between the two groups prior to treatment with regard to disease duration, 24 h-urine protein, FBG, PBG, HBAlc, TC, TG, BVH, BVL, PV, RBCAI, RBCET, BRV, Fib and CRP.

 SKC-YJ treatment effectively reduces the urine protein concentration in DN patients

Compared with the levels prior to treatment, the urine protein concentration after 24 h, FBG, PBG, HBAlc, TC, TG, BVH, BVL, PV, RBCAI, RBCET, blood viscosity, Fib and CRP were decreased (P<0.05) following piperazine and SKC-YJ treatment (Fig. 1). However, piperazine treatment was shown to decrease the levels of 24 h-urine protein, TC, TG and CRP significantly more compared with SKC-YJ treatment (P<0.05).

 SKC-YJ reduces the blood glucose level and improves blood quality

Following treatment, improvements were observed with regard to BVH, BVL, PV, RBCAI, RBCET, BRV and Fib in the two groups (Table III). The comparison results (Fig. 1) indicated that piperazine was able to reduce the BVH and BVL in males, PV in females, and RBCAI, RBCET and Fib significantly following treatment when compared with SKC-YJ treatment.

 SKC-YJ treatment exhibits no toxicity or side-effects in DN treatment

Side-effects in the liver, kidneys and bone marrow were observed in the patients with DN. Compared with the levels prior to treatment, the white blood cell count, neutrophilic granulocyte ratio, RBC count, platelet count, alanine aminotransferase, total bilirubin, direct bilirubin, serum creatinine and blood urea nitrogen parameters were not significantly different following treatment (P>0.05; Table IV). No significant gastrointestinal reactions, including nausea, vomiting, abdominal pain and diarrhea, or allergic reactions, including rash and itching, were observed in the two groups.

 Discussion

The major components of SKC-YJ are Codonopsis pilosula, Poria, Rhizoma Atractylodis Macrocephalae and Astragalus, which have been shown to replenish spleen deficiency. In addition, Rehmannia, Rhizoma Dioscoreae, Fructus Corni, Alisma and Poria are able to enforce liver and kidney function, while leech, Salvia, Angelica and Rhizoma Curcuma have been shown to dredge the main and collateral channels. Furthermore, coix seeds have been used to stop water swelling, rhubarb has been used to achieve detoxification and Fructus Rosae Laevigakea has been used to prevent subtle leakage of the drug effect (6,20).

A previous study demonstrated that major compound formulas based on Astragalus, Rehmannia, Rhizoma Dioscoreae, Poria, Alisma, leeches, Angelica and rhubarb can significantly inhibit early DN advanced glycation end products (AGEs), with an improved therapeutic effect compared with benazepril (24). Furthermore, the protective effects of various doses of rhubarb on C57BL/6J mice have been observed. The results indicated that rhubarb reduces the mRNA and protein expression levels of AGEs in the renal cortex of rats (25); thus, may exert its effect through inhibiting the expression of renal cortex AGEs.

An additional important protein in DN, protein kinase C (PKC), is transported to the cell membrane and activated due to sustained hyperglycemia. Subsequently, PKC activates intracellular transcription factors, enhancing associated transcription factors in the extracellular matrix. In addition, PKC inhibits nitric oxide (NO) synthase activity, reduces the NO level and causes vasoconstriction; PKC also promotes blood clotting and thrombosis. A previous study found that PKC activity in the renal cortex tissue membrane was increased in diabetic patients (26). Furthermore, Schnackenberg et al (27) indicated that the activity levels of antioxidant enzymes (superoxide dismutase and glutathione peroxidase) in diabetic rat kidneys were significantly lower than that in normal rat kidneys. Malondialdehyde (MDA), an oxidative excited-state protein, has been found to be increased significantly in diabetic rats. Following treatment with a compound formula of Astragalus, Euonymus and rhubarb, the expression of MDA reduced significantly compared with the model group, indicating that this compound exhibits a strong antioxidant effect and effectively improves the oxidation involved in DN damage.

Previous studies have demonstrated that during the process of DN, the number and density of podocytes decreases, podocyte slit diaphragm key proteins (nepherin and podocin) are expressed abnormally, and podocyte transmembrane proteins (podocalyxin) are downregulated (28–31). These factors result in the loss or fusion of podocytes and glomerular basement membrane nudity, which leads to damage of the glomerular filtration barrier. When the glomerular basement membrane adheres to the package wall, glomerulosclerosis occurs. Yin et al (32) observed that a formula consisting of Astragalus, leeches and Fructuo Rosae Laevigakea was able to promote podocin synthesis, thereby reducing podocyte injury and maintaining the structure and functional integrity of the podocytes.

The components of SKC-YJ include rhubarb, Astragalus, Angelica sinensis and leech powder, among other ingredients. The therapeutic effect of this TCM on diabetes or DN has been identified by previous studies (33–35). The present study demonstrated that SKC-YJ treatment is effective in improving clinical syndromes, including reducing proteinuria, blood glucose levels, HBAlc, blood lipids and blood viscosity, as well as increasing the serum albumin level. Therefore, SKC-YJ may be used as an effective supplement therapy. Since this study was with a limited number of cases, more multicenter studies with large samples should be needed. more systems biology researches will also be needed to clarify the mechanism of SKC-YJ treatment for DN in the future.

 References Bernal-MizrachiEFatraiSJohnsonJDDefective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cellsJ Clin Invest114928936200410.1172/JCI20042001615467831 McKillopAMAbdel-WahabYHMooneyMHO'HarteFPFlattPRSecretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicityDiabetes Metab283S613S69200212688635 SestiGApoptosis in the beta cells: cause or consequence of insulin secretion defect in diabetes?Ann Med34444450200210.1080/07853890232101239712523500 LiuXLiuLChenPClinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy - a systematic review based on a subgroup analysisJ Ethnopharmacol151810819201410.1016/j.jep.2013.11.02824296085 WangJXiongXCurrent situation and perspectives of clinical study in integrative medicine in ChinaEvid Based Complement Alternat Med2012268542201210.1155/2012/268542 TongXLDongLChenLZhenZTreatment of diabetes using traditional Chinese medicine: past, present and futureAm J Chin Med40877886201210.1142/S0192415X1250065622928822 XieWDuLDiabetes is an inflammatory disease: evidence from traditional Chinese medicinesDiabetes Obes Metab13289301201110.1111/j.1463-1326.2010.01336.x21205111 GuoDZWangYHBianDLiuXRChenZQEffect of blood-activating and stasis-dissolving herbs on renin angiotensin system in diabetic nephropathy ratsZhong Yi Za Zhi175782010(In Chinese) CovingtonMBTraditional Chinese medicine in the treatment of diabetesDiabetes Spectr14154159200110.2337/diaspect.14.3.154 WangXZhangASunHFuture perspectives of Chinese medical formulae: chinmedomics as an effectorOMICS16414421201210.1089/omi.2011.013822734809 AhmedNAdvanced glycation endproducts - role in pathology of diabetic complicationsDiabetes Res Clin Pract67321200510.1016/j.diabres.2004.09.00415620429 SongYZSongSWWuXMEffect of therapy of strengthening Qi and nourishing Yin, removing stasis and dredging collaterals on diabetic nephropathy: An observation of 46 casesJ New Chi Med3232008 MakitaZRadoffSRayfieldEJAdvanced glycosylation end products in patients with diabetic nephropathyN Engl J Med325836842199110.1056/NEJM1991091932512021875967 MiuraJYamagishiSiUchigataYSerum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetesJ Diabetes Complications171621200310.1016/S1056-8727(02)00183-612505751 OnoYAokiSOhnishiKYasudaTKawanoKTsukadaYIncreased serum levels of advanced glycation end-products and diabetic complicationsDiabetes Res Clin Pract41131137199810.1016/S0168-8227(98)00074-69789719 ShimoikeTInoguchiTUmedaFNawataHKawanoKOchiHThe meaning of serum levels of advanced glycosylation end products in diabetic nephropathyMetabolism4910301035200010.1053/meta.2000.773810954022 RosmondRBjörntorpPThe hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and strokeJ Intern Med247188197200010.1046/j.1365-2796.2000.00603.x10692081 FujisawaINishimuraKAsatoRPosterior lobe of the pituitary in diabetes insipidus: MR findingsJ Comput Assist Tomogr11221225198710.1097/00004728-198703000-000043819118 VuksanVWhithamDSievenpiperJLSupplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trialDiabetes Care3028042810200710.2337/dc07-114417686832 LiWLZhengHCBukuruJDe KimpeNNatural medicines used in the traditional Chinese medical system for therapy of diabetes mellitusJ Ethnopharmacol92121200410.1016/j.jep.2003.12.03115099842 LiuYNGuoLZWangLHZhangLQDengWExperimental research on prevention and therapy of diabetic nephropathy by means of boosting qi nourishing yin transforming stasis and downgrade turbidityZhong Hua Zhong Yi Yao Xue Kan26171117132008(In Chinese) ColmanPGThomasDWZimmetPZWelbornTAGarcia-WebbPMooreMPNew classification and criteria for diagnosis of diabetes mellitus. The Australasian Working Party on Diagnostic Criteria for Diabetes MellitusNZ Med J1121391411999 WengWLClinical significance and existing problems of hemorrheologyZhong Guo Wei Xun Huan652002(In Chinese) LvXFMengQYGuoXMEffect of Rehmannia glutinosa water extraction on insulin resistance and gene expression of resistin in type 2 diabetes mellitus ratsZhong Guo Zhong Yao Za Zhi32218221842007(In Chinese) LeeMSSohnCBAnti-diabetic properties of chrysophanol and its glucoside from rhubarb rhizomeBiol Pharm Bull3121542157200810.1248/bpb.31.215418981591 KoyaDHanedaMNakagawaHAmelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetesFASEB J14439447200010698958 SchnackenbergCGWilcoxCSThe SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetesKidney Int5918591864200110.1046/j.1523-1755.2001.0590051859.x11318957 BergTJBangstadHJTorjesenPAOsterbyRBucalaRHanssenKFAdvanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitusMetabolism46661665199710.1016/S0026-0495(97)90010-X9186302 BergTJSnorgaardOFaberJSerum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetesDiabetes Care2211861190199910.2337/diacare.22.7.118610388987 BoltonWKCattranDCWilliamsMERandomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyAm J Nephrol243240200410.1159/00007562714685005 ForbesJMCooperMEThallasVReduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathyDiabetes5132743282200210.2337/diabetes.51.11.327412401719 YinXZhangYWuHProtective effects of Astragalus saponin I on early stage of diabetic nephropathy in ratsJ Pharmacol Sci95256266200410.1254/jphs.FP003059715215651 GuJZhangHChenLXuSYuanGXuXDrug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitusComput Biol Chem35293297201110.1016/j.compbiolchem.2011.07.00322000800 JiLTongXWangHEvidence-Based Medical Research of Xiaoke Pill Study Group: Efficacy and safety of traditional chinese medicine for diabetes: A double-blind, randomised, controlled trialPLoS One8e56703201310.1371/journal.pone.005670323460810 TongXLDongLChenLZhenZTreatment of diabetes using traditional Chinese medicine: Past, present and futureAm J Chin Med40877886201210.1142/S0192415X1250065622928822

Comparison of the treatment results between the two groups with regard to the levels of UAER, FBG, PBG, HBAlc, TG, TC and CRP. *P<0.05, vs. SKC-YJ group prior to treatment; and #P<0.05, vs. control group following treatment. UAER, urinary albumin excretion rate; FBG, fasting blood glucose; PBG, 2 h-postprandial blood glucose; HBAlc, glycosylated hemoglobin; TG, triglycerides; TC, total cholesterol; CRP, C-reactive protein; SKC-YJ, ‘Spleen-kidney-care’ Yiqi Huayu and Jiangzhuo decoction.

Standard indices of blood rheology.

Item Normal index One point Two points Three points
BVH (µPa × sec)a
  Males 5.17–6.16 6.17–6.50 6.51–7.00 >7.00
  Females 4.85–5.78 5.89–6.30 6.31–6.80 >6.80
BVL (µPa × sec)b
  Males 9.48–12.23 12.24–12.69 12.70–13.00 >13.00
  Females 9.35–11.98 11.98–12.10 12.11–12.50 >12.50
PV (µPa × sec)
  Males 1.41–1.63 1.64–1.65 1.66–1.90 >1.90
  Females 1.37–1.58 1.59–1.80 1.81–2.00 >2.00
RBCAI
  Males 5.81–8.67 8.68–8.80 8.81–9.00 >9.00
  Females 5.92–8.74 8.75–8.90 8.91–9.00 >9.00
BRV (µPa × sec)
  Males 8.07–13.23 13.24–13.30 13.31–13.50 >13.50
  Females 8.37–14.06 14.07–14.30 14.31–14.50 >14.50
RBCET (µPa × sec)
  Males 17.00–20.00 20.01–21.00 21.01–22.00 >22.00
  Females 17.00–23.00 23.01–23.50 23.51–24.00 >24.00
Fibrinogen (g/l) 2–4 4–5 5–6 >6

Blood shear rate = 200/sec

blood shear rate = 3/sec. Points assigned as a measure of the blood viscosity of patients, and were a comprehensive indicator, which included the plasma viscosity, haematocrit, erythrocyte deformation, erythrocyte aggregation, platelet rheology and leukocyte rheology. Higher scores indicated a higher blood viscosity. BVH, blood viscosity of high cut; BVL, blood viscosity of low cut; PV, plasma viscosity; RBCAI, red blood cell aggregation index; BRV, whole blood reduced viscosity; RBCET, red blood cell electrophoresis time.

Demographic data of the recruited patients with diabetic nephropathy in the two groups.

Variable Control group Experimental group
Age (years) 60±11 61±9
Gender, male/female (n) 9/7 28/22
Diabetes duration (years) 7.9±5.2 8.4±5.2
24 h-urine protein (g) 2.6±3.35 2.8±2.35
Fasting plasma glucose (mmol/l) 8.1±4.52 8.3±4.34
Postprandial 2 h glucose (mmol/l) 12.9±3.78 14.5±4.34
Glycated hemoglobin (%) 7.5±1.9 7.8±2.5
Cholesterol (mmol/l) 6.26±1.35 6.8±1.52
Triglycerides (mmol/l) 2.58±0.56 2.35±0.79
Fibrinogen (g/l) 5.27 5.62
C-reactive protein (mg/l) 19.25±4.35 18.76±3.48
Whole blood viscosity, high cut (µPa × sec) 200/sec
  Males 6.49±0.68 6.53±0.42
  Females 6.30±0.54 6.31±0.39
Whole blood viscosity, low cut (µPa × sec) 3/sec
  Males 12.73±0.52 12.72±0.62
  Females 12.08±0.39 12.05±0.45
Plasma viscosity (µPa × sec)
  Males 1.62±0.73 1.65±0.86
  Females 1.63±0.65 1.62±0.67
Red blood cell aggregation index
  Males 8.67±0.68 8.79±0.49
  Females 6.75±0.58 6.73±0.42
Red blood cell electrophoresis time (sec)
  Males 23.19±0.32 23.23±0.44
  Females 22.58±0.54 23.01±0.47
Whole blood reduced viscosity (µPa × sec)
  Males 13.55±0.76 13.52±0.63
  Females 13.69±0.65 14.60±0.45

Comparison of the blood test results prior to and following treatment in the two groups.

Index SKC-YJ group Control group
Before After Before After
BVH (µPa × sec)c
  Males 6.53±0.42 5.35±0.27a,b 6.49±0.68 5.56±0.32a
  Females 6.31±0.39 5.05±0.39a,b 6.30±0.54 5.82±0.46a
BVL (µPa × sec)d
  Males 12.72±0.62 11.15±0.62a,b 12.73±0.52 11.86±0.36a
  Females 12.05±0.45 11.12±0.37 12.08±0.39 11.79±0.46
PV (µPa × sec)
  Males 1.65±0.86 1.43±0.78 1.62±0.73 1.58±0.29
  Females 1.62±0.65 1.12±0.64a,b 1.63±0.65 1.78±0.72a
RBCAI
  Males 8.79±0.68 7.28±0.38a,b 8.67±0.68 8.05±0.33
  Females 6.73±0.58 6.05±0.32a,b 6.75±0.58 6.76±0.66
RBCET (sec)
  Males 23.23±0.32 21.01±0.27a,b 23.19±0.32 22.89±0.78
  Females 23.01±0.47 21.02±0.53a,b 22.58±0.54 21.89±0.23
BRV (µPa × sec)
  Males 13.52±0.63 13.08±0.71 13.55±0.76 13.48±0.38
  Females 14.60±0.45 13.78±0.38 13.69±0.65 13.26±0.45
FIB (g/l) 5.62±0.45 3.68±0.38a,b 5.27±0.58 4.78±0.24

P<0.05, vs. control group prior to treatment

P<0.05, vs. control group following treatment

blood shear rate = 200/sec

blood shear rate = 3/sec. Data are presented as the mean ± standard deviation. BVH, blood viscosity of high cut; BVL, blood viscosity of low cut; PV, plasma viscosity; RBCAI, red blood cell aggregation index; RBCET, red blood cell electrophoresis time; BRV, whole blood reduced viscosity; FIB, fibrinogen; M, male; F, female; SKC-YJ, ‘Spleen-kidney-care’ Yiqi Huayu and Jiangzhuo decoction.

Comparison of side-effects prior and subsequent to treatment in the two groups.

Group index SKC-YJ group Control group
Before After Before After
WBC (x109/l) 5.36±3.34 5.78±7.25a,b 5.88±3.86 6.13±4.38a
GR (%) 70.35±8.42 69.52±6.57a,b 69.87±6.64 70.05±4.38a
RBC (x1012/l)
  Males 5.87±3.26 4.85±4.63a,b 6.47±5.37 6.25±3.86a
  Females 3.75±3.26 3.54±3.17a,b 3.26±5.48 4.05±3.44a
PLT(x109/l) 182±7.55 156±6.24a,b 166±4.53 172±3.45a
ALT (µ/l) 25±4.57 32±3.32a,b 32±6.44 28±4.82a
TBIL (µmol/l) 7.38±5.63 10.28±6.86a,b 6.24±4.84 7.63±2.55a
DBIL (µmol/l) 3.65±3.37 5.16±4.18a,b 3.53±4.58 4.62±6.83a
Cr (µmol/l)
  Males 119.5±7.53 110.3±7.86a,b 109.3±5.46 112.6±6.28a
  Females 112.6±4.18 109.7±3.98a,b 108.5±5.25 106.8±2.86a
BUN (mmol/l) 6.7±2.75 6.9±3.33a,b 7.1±3.84 6.9±2.72a

P<0.05, vs. control group prior to treatment

P<0.05, vs. control group following treatment. Data are presented as the mean ± standard deviation. WBC, white blood cell; GR, neutrophilic granulocyte ratio; RBC, red blood cell; PLT, platelet; ALT, alanine aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; Cr, serum creatinine; BUN, blood urea nitrogen; SKC-YJ, ‘Spleen-kidney-care’ Yiqi Huayu and Jiangzhuo.